Clinical trials: Pleural Mesothelioma Malignant Advanced
Malignant Mesothelioma, Perioperative/Postoperative Complications
Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if radiation therapy is effective in preventing metastatic cancer following surgery.
- Trial name
- NCT00006231
- Testing
- quality-of-life assessment, standard follow-up care, radiation therapy
- Where
- 3 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- University of Glasgow
Malignant Mesothelioma
SU5416 in Treating Patients With Malignant Mesothelioma
Phase II trial to study the effectiveness of SU5416 in treating patients who have malignant mesothelioma. SU5416 may stop the growth of malignant mesothelioma by stopping blood flow to the tumor.
- Trial name
- NCT00006014
- Testing
- semaxanib
- Where
- 10 sites in United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor, Advanced Cancer
AMT-151 in Patients With Selected Advanced Solid Tumours
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma, Ovarian Cancer
- Trial name
- NCT05498597
- Testing
- AMT-151
- Where
- 9 sites in Australia, China
- Volunteers
- 30 people
- Sponsor
- Multitude Therapeutics Inc.
Malignant Mesothelioma
Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00458913
- Testing
- bortezomib, cisplatin
- Where
- United Kingdom
- Volunteers
- 82 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Lung Cancer, Malignant Mesothelioma
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer.
- Conditions
- Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Thymoma and Thymic Carcinoma
- Trial name
- NCT00024076
- Testing
- radiofrequency ablation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms
Evaluation of Skin Tests in Biotherapy Allergies
Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases.
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms, Small Cell Bronchial Carcinomas, Bronchial Carcinoma
- Trial name
- ETCABIO (NCT06971848)
- Testing
- Drug skin tests (investigating hypersensitivity to a biotherapy)
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Malignant Mesothelioma
Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
RATIONALE: Drugs used in chemotherapy, such as methotrexate, vinorelbine, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00354393
- Testing
- Cisplatin, Methotrexate, Vinorelbine ditartrate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The Cleveland Clinic
Non Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma.
- Conditions
- Non Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Urothelial Carcinoma, Malignant Mesothelioma
- Trial name
- NCT04173338
- Testing
- Cabozantinib, Pemetrexed
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Augusta University
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Mesothelioma, Malignant
A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
The purpose of this study is to observe the safety of the combination therapy with Yervoy and Opdivo in Japanese participants for the treatment of unresectable advanced/recurrent malignant pleural mesothelioma (MPM).
- Trial name
- NCT05324436
- Where
- Japan
- Volunteers
- 75 people
- Sponsor
- Bristol-Myers Squibb
Malignant Mesothelioma
ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether Onconase plus doxorubicin is more effective than doxorubicin alone in…
- Trial name
- NCT00003034
- Testing
- doxorubicin hydrochloride, ranpirnase
- Where
- 19 sites in United States, Germany and 2 more
- Volunteers
- 300 people
- Sponsor
- Alfacell
Advanced Malignant Mesothelioma, Carcinoma of the Appendix
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RATIONALE: An orientation and patient education program and telephone counseling may help improve the quality of life in patients with peritoneal surface malignancies.
- Conditions
- Advanced Malignant Mesothelioma, Carcinoma of the Appendix, Ovarian Sarcoma, Ovarian Stromal Cancer
- Trial name
- HOPE (NCT01126346)
- Testing
- HIPEC Orientation, Consultation with Survivorship Navigator, Questionnaires
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Pleural Mesothelioma Malignant Advanced
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
The aim of this clinical trial is to assess the effect of treatment with a monoclonal antibody called atezolizumab in patients diagnosed with a type of lung cancer called malignant pleural mesothelioma.
- Trial name
- BEAT-meso (NCT03762018)
- Testing
- Carboplatin, Pemetrexed, Bevacizumab
- Where
- 42 sites in Belgium, France and 4 more
- Volunteers
- 400 people
- Sponsor
- ETOP IBCSG Partners Foundation
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Advanced Malignant Mesothelioma, Epithelial Mesothelioma
Gefitinib in Treating Patients With Malignant Mesothelioma
Phase II trial to study the effectiveness of gefitinib in treating patients who have malignant mesothelioma. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of malignant…
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
- Trial name
- NCT00025207
- Testing
- gefitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Mesothelioma, Epithelial Mesothelioma
Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. This phase II trial is studying how well erlotinib works in treating patients with malignant mesothelioma of the lung
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
- Trial name
- NCT00039182
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Mesothelioma, Epithelial Mesothelioma
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
This phase II trial is studying how well cediranib maleate works in treating patients with malignant mesothelioma that cannot be removed by surgery.
- Conditions
- Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma
- Trial name
- NCT00309946
- Testing
- cediranib maleate
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié